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debate the authors consider the existing literature and
attempt to convince us that the majority, or the minority of
patients with renal artery stenoses should be intervened
upon.
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Introduction
The debate position given to this author may on first glance
appear to be untenable. I hope to convince you that the
opposite stance of not treating patients with renal artery
stenosis (RAS) neglects the opportunity to help some
patients with correctable hypertension and renal dysfunc-
tion. Frankly, either debate position is difficult to defend
given our dearth of solid information in the arena of reno-
vascular disease. As a medical community, we have scant
evidence on the natural history of renal artery stenosis and
the kidneys these arteries are supplying. Furthermore, the
available data is far from convincing especially given the
flawed trial designs in most of the prospective trials.
Clearly, further study on renovascular disease may lead us
to better medical management, patient selection for
intervention, and technical success in those patients that
are intervened upon. I do not believe a global position of
benign neglect of renal artery disease will be in the best
interest of patients with this morbid condition. There are
some current posits that require re-examination. The
following widely held myths need scrutiny:
Myth 1. Atherosclerosis in the renal arteries is
benign
In every arterial bed, the severe consequences of arterial
narrowing secondary to atherosclerosis are recognized. The* Tel.: þ1 216 844 1631.
E-mail address: Vikram.Kashyap@UHHospitals.org.
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thrombosis, embolization, dissection and resultant end-
organ deterioration is well delineated in arterial beds from
the skull to the toe. For instance, the process of discovery
that extracranial cerebrovascular disease caused artery to
artery embolization leading to stroke took decades.1
Furthermore, treatment of the offending lesion to
prevent further stroke and death required rigorous
randomized controlled trials first in symptomatic patients.2
Surgical treatment in the form of endarterectomy removes
the plaque leading to embolization and was found better
than medical therapy in the long-term stroke free survival
of asymptomatic patients3 in the largest surgical trial to
date.4 The limb- and life-saving treatment of peripheral
atherosclerosis is also well documented.5 Similarly, the
recognition and timely management of patients with coro-
nary thrombosis is well recognized as life-saving by both
medical professionals and laypersons.
Why should the kidneys be different? The natural history
of RAS is variable. But, a significant fraction of patients
with RAS have progressive narrowing of the inflow artery to
the functioning renal mass. Using Doppler follow-up, Zierler
and colleagues showed renal arteries with significant
stenoses (>60%) have approximately a 20% progression of
disease per year with 11% progressing to renal occlusion
within 2 years.6 Similarly, using ultrasound to document
renal size, Caps and colleagues showed progression to renal
atrophy in patients with worsening renal artery stenosis.7
It is estimated that chronic kidney disease affects 11% of
the adult population in the United States with nearly 400,000
patients with end-stage renal failure. The morbidity and
mortality of end-stage renal disease is staggering with U.S.
annual mortality rates of greater than 20%.8 Even lesser
degrees of chronic kidney disease can have significant
consequences as the risk of death increases as the glomer-
ular filtration rate (GFR) falls.9 Furthermore, reduced GFR is
independently associated with the cardiovascular morbidity
and hospitalization with severe renal impairment
(GFR < 30 ml/min/1.73 m2). Despite the prevalence of
chronic kidney disease, the relationship to RAS remains
unclear. A significant fraction of patients on hemodialysis
have renal vascular disease implicating that RAS may be an
underappreciated component of renal failure.10Myth 2. Patients with hypertension and renal artery
stenosis have renovascular hypertension
One of the critical problems in assessing patients with renal
artery stenosis is the unclear relationship with concomitant
hypertension. Goldblatt’s compelling studies helped the
medical community understand the causal relationship of
RAS to hypertension over 70 years ago.11 This led to several
reports of curing hypertension by surgical revascularization
a few years later. In pediatric or young adult populations
with congenital or vasculitic causes of renal artery stenosis,
hypertension is closely aligned to the degree of unilateral
RAS. With increasing unilateral stenosis, neurohormonal
changes occur resulting in increased angiotensin II induced
blood pressure elevation. In older populations, essential (or
primary) hypertension is rampant and appraising whether
the RAS is a bystander or the culprit can be challenging foreven the most experienced practitioner. A cavalier attitude
by some is that in our current limitations of understanding
this relationship, the only way to tell is the response after
intervention. That is, treat everyone, help a few. Clearly,
this position of “drive-by” stenting can lead to inappropriate
use of technology, increased costs, and the real possibility of
patient harm in cases of inadvertent renal injury.
Patients with severe hypertension with episodes of
hypertensive crises appear to be the best candidates for
RAS intervention.12 The severity of hypertension may be
seen as the need for increasing antihypertensive agents,
increased dosage or frequency of medication, and sudden
worsening in blood pressure control in an otherwise stable
patient. Despite a plethora of studies to try to understand
this relationship of RAS and hypertension, most studies (i.e.
renal vein renin sampling), are not sufficiently sensitive or
specific to clearly implicate the RAS as the etiologic factor
for the hypertension. A test with prognostic value in this
arena will allow careful selection of patients that require
intervention. Lastly, the current data on blood pressure
reduction in trials is grossly estimated by the number of
medications and/or reduction in dose as a surrogate to
actual blood pressure measurements. The latter is a widely
fluctuating physiological parameter13 and deserves a more
precise assessment.Myth 3. Ischemic nephropathy is any patient with
an escalating creatinine and bilateral RAS
As opposed to unilateral RAS and resultant renovascular
hypertension, bilateral RAS or stenosis in the artery leading
to a single functioning kidney may lead to renal function
loss. Renovascular hypertension may be overdiagnosed, but
RAS causing renal insufficiency and eventual renal loss may
be underappreciated and consequently undertreated.10,14
This condition called “ischemic nephropathy” can be
treated and leads to gratifying improvement in renal
function. However, the tools to assess this in our current
practice are the poorly sensitive serum creatinine (sCr), the
GFR with calculations often based on sCr, and nuclear
medicine testing where the images and interpretation can
sometimes be challenging and lead to differences in
subjective impression between observers.
Unfortunately, most patients with “ischemic nephrop-
athy” presumably have renal function decline secondary to
unrelated chronic renal disease from intrinsic renal
glomerular loss secondary to a host of systemic processes.
This may include inflammatory conditions and oxidative
stress.15
Similar to Myth #2, the likelihood of understanding in
a particular patient whether renal function decline is due
to RAS is often difficult. Many experienced practitioners
have had the gratifying situation of observing rapid
improvement in renal function after treating severe RAS to
a single functioning kidney where the serum markers
clearly delineate residual renal function. Likewise, the
experience of patients with no improvement in their renal
function despite a technically successful procedure is not
uncommon. Salvage of the kidneys is best predicted by the
downward slope of GFR or renal function prior to inter-
vention.16,17 Other prognostic modalities to identify renal
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stand the perfusion deficit in patients with ischemic
nephropathy.18 Novel technologies and assays would allow
us to determine an infarcted renal mass from one that is
ischemic, analogous to stress testing and biomarkers in the
coronary beds.
Myth 4. Renal stenting is an easy procedure to do
well
For the purposes of this debate, we are assuming inter-
vention of the renal arteries means endovascular inter-
vention. There is rich literature on the benefits of surgical
revascularization of the renal arteries.12,13 Surgical revas-
cularization for retrieval of renal function can be accom-
plished with documented durable long-term results in
centers of excellence with a dedicated interest in reno-
vascular surgery.19,20 However, this has largely been sup-
planted by endovascular means21 because of the perceived
lower initial morbidity of a purely percutaneous procedure
as opposed to open revascularization in an elderly pop-
ulation with multiple co-morbidities.
Technical advances have also spurred widespread
adoption of endovascular treatment of RAS. Despite the
rapid increase in renal stenting, trial data have docu-
mented the harm that can occur to the kidneys that we are
trying to protect from deterioration. The kidney does not
have the same discrete functional areas that would alert
a clinician to kidney decline after intervention other than
where serious harm has occurred because of large emboli,
renal infarction, dissection, reperfusion injury, or contrast-
induced renal failure. Some of these may happen more than
we realize. Some possible technical adjuncts that prevent
these complications include: adopting a 6 Fr platform for
intervention with the use of 0.014” guidewires and stent
systems, rapid exchange systems, using a distal protection
device, using a “no touch” technique, anticoagulation/
direct thrombin inhibition, and routine peri-procedure
double anti-platelet therapy with aspirin and clopidogrel.
Clearly in other arterial beds, a distal protection device can
be used to capture atheroembolic debris prior to reaching
the end-organ that we are trying to protect.22 The use of
a distal protection device during renal intervention makes
intuitive sense given the capture of embolic debris in
a significant fraction of cases.23,24 Additional evidence that
atheroembolic material can cause renal parenchymal
damage has been obtained via an ex vivo study using human
arterial plaque specimens.25 Currently, the outcome of
renal PTA/S with a distal protection device is being evalu-
ated in the NIH-supported randomized controlled Cardio-
vascular Outcomes in Renal Atherosclerotic Lesions
(CORAL) trial.26
Myth5.Thedata fromrandomized trials are clear-cut
My debate opponent will try to convince you that multiple
randomized controlled trials clearly show no benefit from
renal artery stenting. One thing is clear: no benefit can be
obtained in patients poorly selected for intervention.
Another critical point: Any benefit from an intervention can
be negated by the poor performance of the procedure.In the recent STAR publication, the investigators
randomized 140 patients to medical therapy or renal artery
stenting for atherosclerotic disease in the renal arteries at 10
European medical centers.27 Patients were eligible for
inclusion if creatinine clearancewas<80mL/min per 1.73m2
and they had a 50% or greater stenosis. The primary endpoint
was a 20% or greater fall in creatinine clearance. This
occurred in 16% of the stent group and 22% of the medication
group (PZ NS). The authors concluded that stent placement
had no clear benefit on preventing renal function decline in
this small study. Of note, only 46 or the 64 patients assigned
to stenting actually had a stent placed. Of great concern was
that 12 of the 64 patients (19%) did not get a stent because
they had <50% stenosis at time of angiography despite the
preoperative imaging (CTA, MRA, etc.) indicating a high-
grade stenosis. One can assume that the medical therapy
group also had a large fraction of patients with insignificant
and benign renal artery stenosis (<50%). The rates of
complications in the stented group including 2 procedure-
related deaths, 1 death from an infected hematoma, 1
renal failure after kidney cholesterol embolism, 2 technical
failures, and 10 femoral hematomas paint a troubling picture
in a group of 46 renal stent procedures.
ASTRAL is an international, multicenter trial that
enrolled 806 patients and randomized them to intervention
or medical management.28 The primary outcome was again
renal function measured as a reciprocal of the serum
creatinine level. The two groups had similar rates of renal
events, cardiovascular events, and death as will be outlined
by our debate opponent. But, this trial has many limita-
tions. Of greatest concern were the inclusion criteria of
patients into the trial. Patients were eligible for enrollment
if they had atherosclerotic disease in the renal arteries and
were considered suitable for endovascular revasculariza-
tion. However, only 59% of enrolled patients had a renal
artery stenosis greater than 70% with essentially the
remainder having 50e70% stenoses. Physicians did not
enroll patients if they thought that renal revascularization
would be beneficialdthe exact target that any RCT in this
arena should focus on. Thus, the patients that we assume
would have the greatest benefit from revascularization
were excluded. Neither the medical management nor the
intervention techniques were standardized and there was
no core laboratory to review the images and corroborate
the renal artery stenoses treated. In fact, often the
severity of the stenosis is overestimated by the inter-
ventionalist when compared to the core laboratory’s non-
biased assessment.29 Thus, many of these patients may
have actually had modest (i.e. 50%) stenoses, rather than
critical stenoses to the kidney they were trying to protect.
Seventeen percent of patients did not undergo intervention
after angiography because the severity of renal artery
stenosis by noninvasive methods was not confirmed on
angiographydone can assume a similar proportion of low-
profile lesions in the medical group. Additionally, 40% of
enrollees had serum creatinine levels <150 umol/L
(<1.7 mg/dL) with a large fraction of these patients with
normal creatinine and only on an average 2.8 antihyper-
tensive agents. What was the indication for treatment in
these patients? In the 359 patients that actually underwent
revascularization, 31 patients (9%) had complications. This
included renal embolization (5), renal artery occlusion (4),
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and cholesterol embolization (3) leading to gangrene and
amputation. With any revascularization procedure for
atherosclerosis, we are trying to “beat” the natural history
of the disease. Patients that have high-grade renal artery
lesions, rapidly falling GFR, and stenoses to the whole renal
mass (i.e. bilateral renal stenoses, stenosis to a single-
functioning kidney) may benefit from renal stenting. But,
trials that enroll large fractions of the patients with benign
lesions and then have high complication rates cannot be
expected to be successful.
Conclusions
With the current data available, one may not be able to
conclude that “vast majority of patients with renal artery
stenoses require intervention”, the provocative position
assigned to this author. On the other hand, the position
“the vast majority of patients with renal artery stenoses do
not require intervention” leaves many patients without an
option that may be kidney- and life-saving. We all agree
that more research is needed in this area. One day, clini-
cians will be able to discern that a particular renal artery
stenosis is the culprit that leads the kidney end-organ to
cause hypertension and/or become ischemic and atrophy.
In the interval, careful evaluation of patients with renal
artery stenosis and renal insufficiency by a collaborative
team of nephrologists and vascular specialists appears to be
warranted. This may offer patients the best opportunity for
long-term renal salvage and survival, whether it be medical
treatment or intervention.References
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Part Two: The Vast Majority of
Patients with Atherosclerotic Renal
Artery Stenoses do not Require
InterventionF. Schneider, J.-B. Ricco *Department of Vascular Surgery, University of Poitiers
Medical Center, 86021 Poitiers, FranceIntroduction
The rate of percutaneous renal artery intervention among
Medicare beneficiaries increased 2.4-fold in 2000 as
compared with 1996 on the premise that associated
hypertension and renal function would be cured.1 To date,
however recent randomized controlled trials (RCT) on
primary stenting for atherosclerotic renal artery stenosis
(ARAS) are not supporting evidence for its use.2 The goal of
this debate was to summarize the evidence on percuta-
neous renal artery stenting for ARAS.
The Clinical Problem
The reported incidence of atherosclerotic renal artery
stenosis (ARAS) in the Medicare population is 0.5% overall,3
but as these patients are often asymptomatic the true
frequency of ARAS is probably higher. ARAS is associated
with hypertension, chronic kidney disease and cardiac
disorders, although it is not clear whether these associa-
tions are causal.4 Nevertheless, patients with ARAS after
adjustment for other traditional risk factors, are at
increased risk for cardiovascular events with a risk of
coronary event that is increased by a factor of two and
markedly decreased survival.5 These outcomes are rare in
patients with ARAS that are treated medically6 and prob-
ably related to distribution and severity of atherosclerosis
in other vascular beds.7,8* Corresponding author. Tel.: þ33 (0) 5 49 44 38 46; fax: þ33 (0) 5
49 50 05 50.
E-mail address: jeanbaptistericco@gmail.com (J.-B. Ricco).Evaluation
ARAS is suspected in patients with the onset of hypertension
after 50 years of age. Confirmation of the diagnosis is made
by imaging. Doppler measurement of renal artery velocity
provides an assessment of the severity of the stenosis.
Alternative methods include MRA, computed tomographic
angiography (CTA) and digital subtraction angiography with
the use of small catheters and limited amounts of contrast
media. All these tests are useful in confirming the diagnosis
of ARAS, but Drieghe et al.9 have shown that even if renal
angiography and color duplex ultrasound correlate well,
both approaches tend to overestimate the ARAS severity
when compared with the measured trans-stenotic pressure
gradient using 0.014 pressure wires. Again none of these
techniques can establish the functional significance of ARAS.
Even the documentation of a trans-stenotic pressure
gradient in ARAS does not necessarily mean that the given
stenosis is the cause of hypertension.
Risk Factors and Medical Treatment
A major confounder related to the treatment of ARAS is
competing risk from other manifestations of atherosclerosis
including stroke, acute coronary syndrome, and congestive
heart failure. The risk of theseevents is greater than the risk of
complications related specifically to ARAS. They reflect
widespread atherosclerotic disease elsewhere.10 In this
context, medical therapy remains the cornerstone of treat-
ment for ARAS. Multi-drug regimens are needed for blood
pressure control including renin-angiotensin-aldosterone
inhibitor, alpha or beta-blocker, diuretic and calcium
channel antagonist. Thedemonstratedbenefitsof antiplatelet
therapy and statins in patients with atherosclerotic disease
also provide support for their use in patients with ARAS.
Prospective Randomized Controlled Trials
Benefit of renal stenting over angioplasty alone
Primary stenting of ARAS was compared to angioplasty
alone in one small RCT.11 The results of this trial were
comparable with those of a meta-analysis that compared
these two techniques.12 There was a 65% reduction in risk
of restenosis with stents at 6-months angiography but there
was no difference in blood pressure or renal outcome.
Primary stenting thus showed a more favorable outcome
with fewer reinterventions than angioplasty for ARAS.13
Benefit of renal artery stenting vs. surgery
Only one RCTcompared renal artery stenting vs. open surgical
revascularization in patients with ARAS.14 Inclusion criteria
were severe hypertension and ARAS >70%. There was no
significant difference in treatment outcome i.e. blood pres-
sure, renal outcome, mid-term patency and complications.
But as surgery was associated with a longer duration of
hospitalization (18 days vs. 10 days), the authors suggest that
renal artery stenting shouldbepreferred to surgery inpatients
who do not need concomitant aortic revascularization.
